PMM2

Across TCGA pan-cancer cohorts, PMM2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PMM2 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PMM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PMM2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

CCRCC, HNSC, and UCEC are the cancer types where PMM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.855	1.000	.034	5	view →
HNSC	DFS	Quartile	All	1.000	0.919	.016	5	view →
UCEC	DFS	Median	All	0.924	0.793	.033	4	view →
LUAD	OS	Median	All	0.602	0.867	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PMM2–CCRCC (DFS)

Open the CCRCC breakdown →